Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
about
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyImpact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studiesRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsEffect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cellsLuteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation.Developing Treatments for Chronic Kidney Disease in the 21st Century.The next generation of therapeutics for chronic kidney diseaseEfficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor.A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation.The role of the JAK/STAT signal pathway in rheumatoid arthritis.Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammation opposite modulation of JAK/STAT and Nrf2 pathways
P2860
Q24658506-259B3A53-979B-498F-AD94-247E73DE174AQ26772850-1154DB72-E4B0-4680-A443-16FAC928C92BQ26851417-11201243-ADF7-43F2-BBDC-296EF1B31E7AQ35668303-F04D0708-9EBF-4116-AA78-60456BFC58C1Q38741546-12606BFC-78A9-4314-B336-845329C79E42Q38773024-5681CA67-5D8D-42E6-8A8C-8129A18558BEQ38781550-47AEE431-2408-4907-AE7E-D2BCBF433DB9Q38845590-E0AA45E8-3DB2-4333-B5B6-628D6029168FQ40169515-5D969002-0A48-49DF-B720-A26A8BA19345Q41143505-ECCF85B3-5085-4BAA-ADD2-87B534B99C48Q43135354-4CE76640-5316-45F7-9DEB-F2D97C7BAA1CQ52626728-C3D3D575-78D9-4545-9041-FFE59691F387Q55027042-B1B39817-0F1C-4E64-B0AE-5E9D0BCD8F8FQ55244957-AE1B704E-845C-4568-BACE-37237A8946E6Q55487787-3EA0BB68-62BA-45D8-A184-086317CC23DDQ58221929-B2C6848E-F0E6-41A0-8A48-083CFF7B629A
P2860
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Tofacitinib: The First Janus K ...... tment of rheumatoid arthritis.
@en
type
label
Tofacitinib: The First Janus K ...... tment of rheumatoid arthritis.
@en
prefLabel
Tofacitinib: The First Janus K ...... tment of rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Tofacitinib: The First Janus K ...... tment of rheumatoid arthritis.
@en
P2093
Deepti Vyas
Eric G Boyce
Jason L Bandy
Kate M O'Dell
P2860
P304
P356
10.1177/1060028013512790
P407
P577
2013-11-01T00:00:00Z